作者: A Karami , A Najafi , M Y Kiaroudi , S M Alavian
DOI:
关键词:
摘要: B hepatitis C virus (HCV) and (HBV) infections are common in patients with end-stage renal disease (ESRD) transplant recipients (1-4). Although both viral replication liver progression accelerated after transplantation, the subsequent long-term impact of chronic HBV HCV is unclear. Chronic failure at particular risk infection. Early studies have demonstrated that benefit from vaccination; however, not all consistently shown benefit. infection among ESRD (5, 6). However, effect on survival patients, transplantation course been adequately defined. The primary goal treatment should be eradication Secondary aims prevention decompensated cirrhosis or hepatocellular carcinoma through sustained suppression. When determining optimal regimen, several questions must addressed which antiviral agents, whom to treat, when start therapy. Interferon has direct potent immunomodulatory actions (7). Development screening serological tests for detection significantly reduced incidence rates these (8). resulting still a major concern kidney (9). It certain immunosuppressive agents facilitate higher